Find Vactosertib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1352608-82-2, Ew-7197, Ew 7197, Tew-7197, Tew 7197, Ew7197
Molecular Formula
C22H18FN7
Molecular Weight
399.4  g/mol
InChI Key
FJCDSQATIJKQKA-UHFFFAOYSA-N
FDA UNII
6T4O391P5Y

Vactosertib
Vactosertib is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells.
1 2D Structure

Vactosertib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline
2.1.2 InChI
InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)
2.1.3 InChI Key
FJCDSQATIJKQKA-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4
2.2 Other Identifiers
2.2.1 UNII
6T4O391P5Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ew-7197

2. N-((4-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

2.3.2 Depositor-Supplied Synonyms

1. 1352608-82-2

2. Ew-7197

3. Ew 7197

4. Tew-7197

5. Tew 7197

6. Ew7197

7. Chembl3260567

8. 6t4o391p5y

9. 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline

10. N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

11. N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo-[1,5-a]pyridin-6-yl-1h-imidazole-2-methanamine

12. N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1h-imidazole-2-methanamine

13. N-((4-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

14. N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]methyl]-2-fluoroaniline

15. Vactosertib [inn]

16. Vactosertib [who-dd]

17. Schembl250076

18. Unii-6t4o391p5y

19. Gtpl8107

20. Dtxsid401010181

21. Hms3674i03

22. Bcp18384

23. Ex-a1738

24. Nov-1301

25. Am9667

26. Bdbm50015639

27. Mfcd28348363

28. S7530

29. Akos027250746

30. Zinc113391423

31. Ccg-264709

32. Cs-5679

33. Db15310

34. Sb17272

35. Ncgc00386413-01

36. Ncgc00386413-02

37. Ac-29028

38. As-10150

39. Bt168124

40. Hy-19928

41. N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methyl-2-pyridyl)-2-imidazolyl]methyl]-2-fluoroaniline

42. Sy235585

43. Ds-001727

44. A14213

45. Q27077252

46. 1h-imidazole-2-methanamine, N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-(1,2,4)triazolo(1,5-a)pyridin-6-yl-

47. 1h-imidazole-2-methanamine,n-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-

48. 2-fluoro-n-((4-(6-methylpyridin-2-yl)-5-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-1h-imidazol-2-yl)methyl)aniline

49. N-((5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

50. N-(2-fluorophenyl)-4-([1,2,4]triazolo[1,5-a]pyridine-6-yl)-5-(6-methyl-2-pyridyl)-1h-imidazole-2-methaneamine

2.4 Create Date
2012-01-23
3 Chemical and Physical Properties
Molecular Weight 399.4 g/mol
Molecular Formula C22H18FN7
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count5
Exact Mass399.16077177 g/mol
Monoisotopic Mass399.16077177 g/mol
Topological Polar Surface Area83.8 Ų
Heavy Atom Count30
Formal Charge0
Complexity566
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty